GlobeNewswire

Transparency notification received from The Capital Group

Share

Mechelen, Belgium; 3 March 2021; 22.15 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc.

Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 26 February 2021 from The Capital Group Companies, Inc., who notified that it holds 9.91% of the current 65,411,767 outstanding Galapagos shares. The Capital Group Companies, Inc. thus crossed below the 10% threshold of Galapagos’ voting rights by disposing of voting securities on 22 February 2021. The full transparency notice is available on the Galapagos website.

About Capital Group
Capital Group controls Capital Bank & Trust Company and Capital Research & Management Company through its direct subsidiary Capital Group International, Inc. (“CGII”), controls four CGII investment management companies (Capital International, Inc.; Capital International Limited, Capital International Sàrl; and Capital International K.K.), which all together hold 6,483,973 of Galapagos’ voting rights, consisting of ordinary shares, which represents 9.91%.

About Galapagos
Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contacts

Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
ir@glpg.com

Media:
Carmen Vroonen
Global Head Communications & Public Affairs
+32 473 824 874

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900
communications@glpg.com





1  Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market



Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

GrandVision reports 1Q21 revenue of €899 million and adjusted EBITA of €79 million23.4.2021 07:00:00 CEST | Press release

GrandVision reports 1Q21 revenue of €899 million and adjusted EBITA of €79 million Schiphol, the Netherlands – 23 April 2021. GrandVision N.V. publishes its First Quarter 2021 trading update. Due to the exceptional nature of the year 2020, GrandVision will also include in the present press release comparisons versus 2019. Highlights • GrandVision continues to show resilience in the first quarter despite the most recent COVID-19 related government restrictions in Europe and Latam • At constant exchange rates, revenue declined by -0.7% compared with 1Q20 to €899 million from €926 million in 1Q20 (1Q19: €974m) • Comparable revenue declined by -1.5% versus 1Q20 and on a 2019 basis, -10.8% versus 1Q19 • Adj. EBITA increased by 98.1% at constant exchange rates to €79 million from €41 million in 1Q20 (1Q19: €107m). Continued cost discipline, structural improvements in certain territories and improved product and price mix contributed to the underlying performance • Adj. EBITA margin at 8.8%,

Corbion appoints Aurélie Dalbiez as Chief Human Resources Officer23.4.2021 07:00:00 CEST | Press release

Corbion announces the appointment of Aurélie Dalbiez as Chief Human Resources Officer and member of the Executive Committee as of 1 July 2021. Mrs. Dalbiez (a French national) currently is Head of HR for the Capsules and Health Ingredients business at Lonza, based in Basel, Switzerland. Prior to that, she worked for 12 years in various HR roles at Novartis. She started her career at Deutsche Bank before working for Capital International, a global investment company. CEO Olivier Rigaud commented: "I am really pleased to welcome Aurélie to the ExCo team as a seasoned HR leader who partners closely with the business to develop talent, drive culture, engagement, continuous improvement, and customer intimacy. Her appointment will also further enhance the diversity of our ExCo." Mrs. Dalbiez brings a multi-cultural background and perspective. She lived in the United States as a child, earned her university degree in International Business in Lyon, France and worked internationally throughout

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy23.4.2021 07:00:00 CEST | Press release

About 90,000 women globally die from endometrial cancer each year1VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly)Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a specific therapy Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. Endometrial cancer is the most common gynecologic can

Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies23.4.2021 06:01:00 CEST | Press release

Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis Mechelen, Belgium;23April 2021;06.01 CET; –Galapagos NV (Euronext & Nasdaq: GLPG) today report that their collaboration partnerGilead Sciences K.K. (“Gilead”) and Eisai Co., Ltd. (“Eisai”)today announced that Gilead submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis (UC).Filgotinib is a new oral Janus kinase (JAK) inhibitor approved in Japan in September 2020 for the treatment of rheumatoid arthritis. This latest regulatory submission is based on data from the randomized, double-blind, placebo-controlled Phase 2b/3 SELECTION study evaluating the efficacy and safety of filgotinib for the induction and maintenance of remission in patients with moderately to severely active ulcerative colitis who have had a

Camposol Holding PLC Invitation to the Presentation of Fourth Quarter and Audited Full Year 2020 Financial Results23.4.2021 02:00:00 CEST | Press release

Camposol Holding PLC will announce the results for the full year 2020 on Thursday, April 29, 2021. In connection with the release, a telephone conference will be held at 9:30 a.m. (Lima) as described below. The presentation will be published at 8:30 a.m. (Lima) and will be available on the Company's website. In connection with the earnings release Samuel Dyer Coriat, CEO, and Andrés Colichón Sas, CFO, will host a conference call presentation and a Q&A session at 9:30 a.m. (Lima). To participate in the conference call, please use the following numbers: London, UK Local +0800 028 8438 US/Canada International +1 409 981 0728 Zurich, Switzerland, Local +044 580 1740 Oslo, Norway, Local +47 8001 6162 Colombia, National Free Phone +01 800 518 5094 Chile, National Free Phone +56 800 914 686 Peru, National Free Phone +51 0800 71470 Participants will be asked for their name and conference ID. The Camposol conference ID is: 2466977 Audio access for the meeting is available by dialing the above-m

CrossAmerica Partners LP Maintains Quarterly Distribution22.4.2021 22:30:00 CEST | Press release

•Quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 Allentown, PA, April 22, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Maintains Quarterly Distribution Quarterly distribution of $0.5250per unit attributable to the firstquarter of 2021 ALLENTOWN, PA (April 22, 2021) – CrossAmerica Partners LP (NYSE: CAPL) announced today that the Board of Directors of its general partner has approved a quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 (annualized $2.10 per unit). The distribution attributable to the first quarter is payable on May 11, 2021 to all unitholders of record on May 4, 2021. CrossAmerica will host a conference call on May 11th at 9:00 a.m. Eastern Time to discuss first quarter earnings results, which will be released after the market closes on Monday, May 10. About CrossAmerica Partners LP CrossAmerica Partners is a leading wholesale distributor of motor fuels, convenience store operator, and owner and